company background image
A099

BioPlus KOSDAQ:A099430 Stock Report

Last Price

₩31.30k

Market Cap

₩440.7b

7D

-2.2%

1Y

n/a

Updated

10 Aug, 2022

Data

Company Financials +
A099430 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

A099430 Stock Overview

BioPlus Co., Ltd. engages in the research and development, production, and sale of bio products in South Korea.

BioPlus Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioPlus
Historical stock prices
Current Share Price₩31,300.00
52 Week High₩43,000.00
52 Week Low₩20,350.00
Beta0
1 Month Change5.57%
3 Month Change28.81%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-3.54%

Recent News & Updates

Shareholder Returns

A099430KR Medical EquipmentKR Market
7D-2.2%2.7%1.7%
1Yn/a-25.1%-21.9%

Return vs Industry: Insufficient data to determine how A099430 performed against the KR Medical Equipment industry.

Return vs Market: Insufficient data to determine how A099430 performed against the KR Market.

Price Volatility

Is A099430's price volatile compared to industry and market?
A099430 volatility
A099430 Average Weekly Movement8.1%
Medical Equipment Industry Average Movement6.7%
Market Average Movement6.5%
10% most volatile stocks in KR Market11.0%
10% least volatile stocks in KR Market4.0%

Stable Share Price: A099430 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: A099430's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
200358Hyun-Kyu Junghttps://www.ubioplus.co.kr

BioPlus Co., Ltd. engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms.

BioPlus Co., Ltd. Fundamentals Summary

How do BioPlus's earnings and revenue compare to its market cap?
A099430 fundamental statistics
Market Cap₩440.69b
Earnings (TTM)₩11.27b
Revenue (TTM)₩40.61b

39.1x

P/E Ratio

10.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A099430 income statement (TTM)
Revenue₩40.61b
Cost of Revenue₩15.50b
Gross Profit₩25.11b
Other Expenses₩13.84b
Earnings₩11.27b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)800.36
Gross Margin61.83%
Net Profit Margin27.75%
Debt/Equity Ratio1.8%

How did A099430 perform over the long term?

See historical performance and comparison